The estimated Net Worth of George Massaro is at least 7.67 百万$ dollars as of 15 May 2024. Mr. Massaro owns over 332 units of Charles River Laboratories International stock worth over 1,133,469$ and over the last 21 years he sold CRL stock worth over 6,207,521$. In addition, he makes 328,606$ as Independent Director at Charles River Laboratories International.
George has made over 90 trades of the Charles River Laboratories International stock since 2005, according to the Form 4 filled with the SEC. Most recently he sold 332 units of CRL stock worth 78,226$ on 15 May 2024.
The largest trade he's ever made was exercising 16,710 units of Charles River Laboratories International stock on 3 November 2014 worth over 696,306$. On average, George trades about 2,055 units every 50 days since 2004. As of 15 May 2024 he still owns at least 5,855 units of Charles River Laboratories International stock.
You can see the complete history of Mr. Massaro stock trades at the bottom of the page.
George E. Massaro is an Independent Director of Charles River Laboratories International Inc. He Director and Vice Chairman of Huron Consulting Group, Inc., a management consulting company, since May 2010. Mr. Massaro was non-Executive Chairman of the Board of Huron Consulting Group from July 2009 to May 2010, Director and Vice Chairman of Huron Consulting Group since June 2004 (Vice Chairman since March 2005), Chief Operating Officer of Huron Consulting Group, Inc. and Huron Consulting Services LLC from June 2003 until March 2005, and Managing Director of Huron Consulting Services LLC from August 2002 to May 2003. He was the Managing Partner of Arthur Andersen LLP's New England practice from 1998 to 2002. Mr. Massaro also served as a director of Eastern Bank Corporation, an independent mutual bank holding company in New England from 2003 through 2017. Mr. Massaro has been a director since 2003. Mr. Massaro has more than 35 years of accounting and auditing experience with expertise in a broad range of areas. As a former managing partner of a major accounting firm, Mr. Massaro brings a deep knowledge of financial reporting, and auditing and tax matters applicable to a variety of industries. Mr. Massaro also provides business acumen from his numerous senior positions at Huron Consulting, as well as his service on boards of other companies. As a result of his extensive background in public accounting and prior experience at Arthur Andersen, Mr. Massaro qualifies as an "audit committee financial expert" under SEC guidelines.
As the Independent Director of Charles River Laboratories International, the total compensation of George Massaro at Charles River Laboratories International is 328,606$. There are 11 executives at Charles River Laboratories International getting paid more, with James Foster having the highest compensation of 17,722,100$.
George Massaro is 72, he's been the Independent Director of Charles River Laboratories International since 2003. There are 3 older and 18 younger executives at Charles River Laboratories International. The oldest executive at Charles River Laboratories International Inc. is Stephen Chubb, 76, who is the Independent Director.
Over the last 21 years, insiders at Charles River Laboratories International have traded over 220,588,205$ worth of Charles River Laboratories International stock and bought 18,392 units worth 3,841,397$ . The most active insiders traders include James C Foster、Richard F Wallman、David P Johst. On average, Charles River Laboratories International executives and independent directors trade stock every 14 days with the average trade being worth of 2,223,188$. The most recent stock trade was executed by Joseph W La Plume on 8 August 2024, trading 1,780 units of CRL stock currently worth 354,861$.
charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro
Charles River Laboratories International executives and other stock owners filed with the SEC include: